Veracyte Q3 2026 earnings

VCYT · 2026-11-04 16:08 AMC ET · 8-K on SEC

Solid profitability and cash generation with mid-teens revenue growth, offset by a slight deceleration in adjusted EBITDA and a gross margin decline.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$151.8M+15%—Ex. 99.1, Financial Results
EPS (GAAP)$0.38+0.14—Ex. 99.1, Financial Results
EPS (adjusted)$0.51Flat—Ex. 99.1, Financial Results
Net income$31.5M+$12.4M—Ex. 99.1, Financial Results
Adj. EBITDA$41.2M+4%—Ex. 99.1, Financial Results
Adj. EBITDA margin27.2%+1.2 pp—Ex. 99.1, Financial Results

Revenue breakdown

SegmentActualYoYShare of revenueNote
Decipher Prostate$92.3M+12%61%Volume below expectations
Afirma$51.5M+19%34%Outperformed
Product revenue$4.6M+40%3%Driven by Prosigna IVD adoption
Biopharmaceutical and other revenue$0.7M-14%<1%Decrease from prior year

Margins and costs

  • Gross margin 71% (prior 69%, change +2 pp)
  • Operating expenses $90.5M (+24% YoY)
  • One-offs in the quarter Impairment of assets; Acquisition related expenses
  • Effective tax rate -68.5% (prior-year -1.2%, year-to-date -10.4%)
  • Non-GAAP bridge Adds back amortization of intangible assets, stock-based compensation, acquisition-related expenses, and other adjustments to GAAP measures.

KPIs

MetricActualPrior quarterPrior yearChange
Total volume52,744 tests50,967 tests45,898 tests+3.5%
Testing volume49,498 tests48,389 tests43,631 tests+3.4%

Guidance

MetricGuidePrior guideChange
Total revenue$590M-$593M$590M-$596M-$3M
Testing revenue$571M-$573M$576M-$582M-$5M
Adjusted EBITDA margin>26%>26%—

What drove it

  • Revenue story Total revenue grew 15% to $151.8M, driven by Afirma (+19%) and Decipher Prostate (+12%). Product revenue surged 40% to $4.6M.
  • EPS story GAAP EPS improved to $0.38 (+$0.14 YoY) driven by higher net income; adjusted EPS was flat YoY.
  • One-off check Impairment of assets and acquisition-related expenses are non-recurring items affecting GAAP results.

The good

  • GAAP net income of $31.5M (20.8% margin)
  • Cash from operations of $40.3M
  • Product revenue growth of 40%
  • Afirma revenue growth of 19%

The bad

  • Decipher Prostate volume below expectations
  • Adjusted EBITDA growth decelerated to 4%
  • Gross margin declined to 71%

The ugly

  • none

Open questions

  • What specific factors caused Decipher Prostate volume to fall short of expectations?
  • Why did adjusted EBITDA growth slow despite continued revenue growth?
Full release

Veracyte (VCYT) earnings release, November 4, 2026

Veracyte, Inc. (VCYT) · Form 8-K, Item 2.02 · Filed · SEC filing

Veracyte Announces Third Quarter 2026 Financial Results

Grew total revenue to $151.8 million and testing revenue to $146.4 million, representing 15% year-over-year growth

Announces $100 million share repurchase program

SOUTH SAN FRANCISCO, Calif., November 4, 2026 --- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2026.

“We delivered solid third quarter results supported by strong profitability and cash generation,” said Marc Stapley, chief executive officer of Veracyte. “Afirma outperformed, while Decipher Prostate volume was below our expectations. We remain confident in the long-term outlook of our business and expect a number of evidence-based catalysts to support growth in our core franchises while also advancing our breast and bladder strategies. As we execute on these opportunities, our differentiated financial profile enables us to continue investing in the business to drive long-term growth.”

Key Financial Highlights

For the three-month period ended September 30, 2026, as compared to the same period in 2025:

• Increased total revenue by 15% to $151.8 million and testing revenue by 15% to $146.4 million, driven by Decipher Prostate growth of 12% to $92.3 million and Afirma growth of 19% to $51.5 million.

• Increased total volume by 15% to 52,744 tests and testing volume by 13% to 49,498 tests, driven by approximately 29,900 Decipher Prostate tests, as well as approximately 19,100 Afirma tests. Volume for each test grew 12% year-over-year.

• Increased product revenue by 40% to $4.6 million, driven by strong adoption of Prosigna IVD following the release of the phase III OPTIMA trial results at ASCO.

• Recorded GAAP net income of $31.5 million, or 20.8% of revenue, and delivered adjusted EBITDA of $41.2 million, or

27.2% o f revenue.

• Generated $40.3 million of cash from operations to end the quarter with $370.5 million of cash, cash equivalents, and short-term investments as of September 30, 2026.

Key Business Highlights

• Acquired Convergent Genomics, Inc., expanding our urology portfolio with a urinary tumor DNA testing platform to help guide bladder cancer care across the patient journey.

• Secured Medicare reimbursement for our Prosigna Breast Risk of Recurrence (ROR) test in the U.S. for eligible patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer.

• Further expanded the clinical evidence of the Decipher Prostate test, with new predictive evidence supporting its use with treatment intensification decisions across intermediate-risk and very high-risk prostate cancer.

• Surpassed a key milestone, with more than 1 million patients served to date with Veracyte's tests.

• Announced that the Board of Directors has authorized a share repurchase program for up to $100 million of common stock.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Note Regarding Use of Non-GAAP Financial Measures."

Third Quarter 2026 Financial Results

Total revenue for the third quarter of 2026 was $151.8 million, an increase of 15% compared to $131.9 million reported in the third quarter of 2025. Testing revenue was $146.4 million, an increase of 15% compared to $127.8 million in the third quarter of 2025, driven by growth in our Decipher Prostate and Afirma tests. Product revenue was $4.6 million, an increase of 40% compared to $3.3 million in the third quarter of 2025, driven by strong adoption of Prosigna IVD following the release of the phase III OPTIMA trial results at ASCO. Biopharmaceutical and other revenue was $0.7 million, compared to $0.8 million in the third quarter of 2025.

Total gross margin for the third quarter of 2026 was 71%, compared to 69% in the third quarter of 2025. Non-GAAP gross margin was 74%, compared to 73% in the third quarter of 2025.

Operating expenses were $90.5 million for the third quarter of 2026 compared to $68.3 million in the third quarter of 2025. Non-GAAP operating expenses grew 24% to $72.9 million compared to $58.6 million in the third quarter of 2025.

GAAP Net income for the third quarter of 2026 was $31.5 million, an increase of $12.4 million compared to the third quarter of 2025. Diluted net earnings per common share was $0.38, an improvement of $0.14 compared to the third quarter of 2025. Non-GAAP diluted net earnings per common share was $0.51, flat compared to the third quarter of 2025. Net cash provided by operating activities in the first nine months of 2026 was $121.3 million, an improvement of $37.6 million compared to the same period in 2025.

Adjusted EBITDA for the third quarter of 2026 was $41.2 million, an improvement of 4% compared to the third quarter of 2025, representi ng 27.2% of revenue.

2026 Financial Outlook

Veracyte now expects 2026 total revenue guidance of $590 million to $593 million, representing 14% to 15% growth, compared to prior guidance of $590 million to $596 million. This reflects testing revenue of $571 million to $573 million, representing 16% growth, compared to prior guidance of $576 million to $582 million, with minimal revenue contribution from recently launched tests. Further, the company continues to expect adjusted EBITDA margin of greater than 26% for 2026.... (truncated)ion-related expenses, and other adjustments. Any associated estimate of these items and their impact on GAAP performance for the guidance period could vary materially. For more information on the non-GAAP financial measures, please refer to the section titled “Note Regarding Use of Non-GAAP Financial Measures” at the end of this press release.

Share Repurchase Program

Veracyte announced today that its Board of Directors has authorized a share repurchase program for up to $100 million of its common stock. Under the repurchase program, the company may repurchase shares through open market purchases, privately negotiated transactions or by other methods from time to time. Any open market repurchases will be structured to comply with applicable federal securities laws, including the pricing and volume requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing, manner, price, and amount of any repurchases will be determined at the company's discretion based on a variety of factors, including market conditions, the trading price of the company's common stock, the company's financial condition and results of operations, capital requirements, general business conditions, alternative investment opportunities, and other factors the company deems relevant. The repurchase program does not obligate the company to acquire any specific number of shares, may be modified, suspended, or discontinued at any time without prior notice at the discretion of the Board of Directors, and will expire after 12 months. The company currently expects to fund the repurchase program from available cash and cash equivalents.

Conference Call and Webcast Details

Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/kgcmbvpd. The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care.

Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the

Afirma® Genomic Sequencing Classifier test,

Decipher® Bladder Genomic Classifier test,

Decipher® Prostate Genomic Classifier test,

Prosigna® Breast Risk of Recurrence test, and the

TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on

LinkedIn or

X (Twitter).

Financial statements

Income Statement

VERACYTE, INC. – CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited) – Three Months Ended September 30, – 2026VERACYTE, INC. – CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited) – Three Months Ended September 30, – 2025VERACYTE, INC. – CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited) – Nine Months Ended September 30, – 2026VERACYTE, INC. – CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited) – Nine Months Ended September 30, – 2025
Revenue:
Testing revenue146,419127,756427,171357,328
Product revenue4,6263,30112,16310,479
Biopharmaceutical and other revenue7098151,8128,702
Total revenue151,754131,872441,146376,509
Cost of revenue: (1)
Cost of testing revenue38,47733,777108,09294,444
Cost of product revenue2,7663,0157,1726,186
Cost of biopharmaceutical and other revenue1421,0913577,361
Intangible asset amortization - cost of revenue3,2652,7078,7137,959
Total cost of revenue44,65040,590124,334115,950
Gross profit107,10491,282316,812260,559
Operating expenses: (1)
Research and development32,15915,98188,69949,965
Selling and marketing28,65224,45584,07174,225
General and administrative29,30227,27880,42593,417
Impairment of assets20,505
Intangible asset amortization - operating expenses4226221,4221,865
Total operating expenses90,53568,336254,617239,977
Income from operations16,56922,94662,19520,582
Other income (loss), net4,553-4,05715,4246,985
Income before income taxes21,12218,88977,61927,567
Income tax provision (benefit)-10,381-248-8,0812,363
Net income31,50319,13785,70025,204
Earnings per share:
Basic0.390.241.070.32
Diluted0.380.241.040.32
Shares used to compute earnings per common share:
Basic80,500,40678,725,13980,006,66378,384,184
Diluted82,783,91579,691,70382,204,30779,946,386

Income Statement

Three Months Ended September 30,

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cost of revenue9955403,0541,668
Research and development2,7421,9498,3406,023
Selling and marketing2,7342,1027,8396,258
General and administrative7,4886,16621,57318,751
Total stock-based compensation expense13,95910,75740,80632,700

Income Statement

VERACYTE, INC. – RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES – (Unaudited) – Three Months Ended September 30, – 2026VERACYTE, INC. – RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES – (Unaudited) – Three Months Ended September 30, – 2025VERACYTE, INC. – RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES – (Unaudited) – Nine Months Ended September 30, – 2026VERACYTE, INC. – RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES – (Unaudited) – Nine Months Ended September 30, – 2025
Reconciliation of Non-GAAP Cost of Revenue:
GAAP cost of testing revenue38,47733,777108,09294,444
Stock-based compensation expense-994-555-3,052-1,543
Acquisition related expenses (1)-131-131
Other adjustments (2)-316-954
Non-GAAP cost of testing revenue37,03633,222103,95592,901
GAAP cost of product revenue2,7663,0157,1726,186
Stock-based compensation expense-1-2-2
Other adjustments (2)-1,41811-1,450
Non-GAAP cost of product revenue2,7651,5977,1814,734
GAAP cost of biopharmaceutical and other revenue1421,0913577,361
Stock-based compensation expense15-123
Non-GAAP cost of biopharmaceutical and other revenue1421,1063577,238
Reconciliation of Non-GAAP Gross Margin:
GAAP Gross Profit107,10491,282316,812260,559
GAAP Gross Margin70.669.271.869.2
Amortization of intangible assets3,2652,7078,7137,959
Stock-based compensation expense9955403,0541,668
Acquisition related expenses (1)131131
Other adjustments (2)3161,4189431,450
Non-GAAP Gross Profit111,81195,947329,653271,636
Non-GAAP Gross Margin73.772.874.772.1

Cash Flow

VERACYTE, INC. – CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – (Unaudited) – Nine Months Ended September 30, – 2026VERACYTE, INC. – CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – (Unaudited) – Nine Months Ended September 30, – 2025
Operating activities
Net income85,70025,204
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization16,24716,117
Loss on disposal of property, plant and equipment36715
Stock-based compensation40,80632,700

Balance Sheet (in thousands)

VERACYTE, INC. – CONDENSED CONSOLIDATED BALANCE SHEETS – September 30, – 2026 – (Unaudited)VERACYTE, INC. – CONDENSED CONSOLIDATED BALANCE SHEETS – December 31, – 2025 – (See Note 1)
Current assets:
Cash and cash equivalents199,828362,578
Short-term investments170,70450,311
Accounts receivable56,78844,660
Supplies25,81820,546
Prepaid expenses and other current assets14,74010,281
Total current assets467,878488,376
Property, plant and equipment, net24,87022,192
Right-of-use assets, operating leases35,09736,599
Intangible assets, net184,88389,148
Goodwill855,575767,154
Restricted cash1,6461,648
Other assets3,307902
Total assets1,573,2561,406,019
Current liabilities:
Accounts payable9,7104,593
Accrued liabilities60,08748,801
Current portion of deferred revenue8641,160
Current portion of acquisition-related contingent consideration6,7341,332
Current portion of operating lease liabilities6,8144,051
Total current liabilities84,20959,937
Deferred tax liabilities1,616646
Acquisition-related contingent consideration, net of current portion17,245257
Operating lease liabilities, net of current portion33,92235,603
Other liabilities3,000
Total liabilities139,99296,443
Total stockholders’ equity1,433,2641,309,576
Total liabilities and stockholders’ equity1,573,2561,406,019

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to our 2026 financial and operating results; our share repurchase program, including the timing, amount and source of funds for any repurchases of shares; and our intentions with respect to the development, launch, commercialization, adoption, and reimbursement of our tests and products. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “could,” “would,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” “strategic,” “outlook,” “guidance,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; our ability to execute on our business strategies relating to our acquisitions, including C2i Genomics and Convergent Genomics, Inc., integration of the business and the realization of expected benefits and synergies; our ability to demonstrate the validity and utility of our genomic tests and biopharma and other offerings; our ability to continue executing on our business plan; our ability to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine and other regional conflicts on European economies; the impact of foreign currency fluctuations, volatile interest rates, inflation, the impact of legislation and policies enacted by the current U.S. administration; turmoil in the global banking and finance system; the ongoing conflict in the Middle East; and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise.

Note Regarding Use of Non-GAAP Financial Measures... (truncated)al measures prepared in accordance with generally accepted accounting principles (GAAP), this press release and the accompanying tables contain, and reference certain non-GAAP results including non-GAAP gross margin, non-GAAP operating expenses, adjusted EBITDA, adjusted EBITDA as a percentage of revenue (also referred to as adjusted EBITDA margin), non-GAAP net income, and non-GAAP earnings per share (EPS) and non-GAAP weighted average shares outstanding. These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.

We use non-GAAP financial measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP financial measures we present may be different from those used by other companies, including similarly titled measures.

We compute these non-GAAP measures by adjusting the applicable GAAP measure to remove the impact of certain recurring and non-recurring charges and gains and to adjust for the impact of income tax items related to such adjustments to our GAAP financial statements. In particular, we exclude amortization of acquired intangible assets, acquisition-related expenses relating to our acquisitions of Decipher Biosciences, HalioDx and C2i Genomics, impairment charges associated with the nCounter license and other biopharmaceutical services related to HalioDx intangible assets, all stock-based compensation and certain costs related to restructuring from all of our non-GAAP financial measures as well as depreciation and income tax items from our adjusted EBITDA and adjusted EBITDA as a percentage of revenue. Beginning in the second quarter of 2024, we changed our non-GAAP policy to exclude all stock-based compensation to align with our peers and we have also excluded all stock-based compensation from our prior period non-GAAP financial measures. Management has excluded the effects of these items in non-GAAP financial measures to help investors gain a better understanding of the core operating results and future prospects of the company, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts. The company encourages investors to carefully consider its results under GAAP, together with its supplemental non‐GAAP information and the reconciliation between these presentations. See “Reconciliation of U.S. GAAP to Non-GAAP Financial Measures” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.

1. Cost of revenue, research and development, sales and marketing and general and administrative expenses include the following stock-based compensation related expenses:

# # #

Investors:

Kelly Gura investors@veracyte.com

Media:

Molly Cornbleet media@veracyte.com

+1-650-351-8780

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Veracyte earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.